Table 1.
Some of the Ongoing Trials Evaluating Various Targets for Post-Allogeneic Stem Cell Transplantation Strategies
| Target | Drug(s) | Clinical Phase | Endpoints | Status | Identifier |
|---|---|---|---|---|---|
| FLT3 | |||||
| Crenolanib | II | PFS; DFS; OS; GVHD; 100-day TRM | Recruiting | NCT02400255 | |
| Gilteritinib | III | RFS, OS, GVHD, EFS | Active, not recruiting | NCT02997202 | |
| TP53 | |||||
| APR-246 + Azacytidine | II | Safety, tolerability, 1-year RFS | Recruiting | NCT03931291 | |
| Hh | |||||
| Glasdegib | III | DFS | Not yet recruiting | NCT04168502 | |
| DNMT | |||||
| Low-dose azacytidine | II | OS; relapse rate; safety | Recruiting | NCT01995578 | |
| Azacytidine+ valproic acid | II | OS; time to relapse | Recruiting | NCT02124174 | |
| Oral azacytidine (AMADEUS) | III | RFS, OS, NRM, GVHD | Recruiting | NCT04173533 | |
| SGI-110+ DLI | II | DFS, OS | Not yet recruiting | NCT03454984 | |
| BCL-2 | |||||
| Venetoclax+ azacytidine | I | MTD; OS, RFS; GVHD | Recruiting | NCT03613532 | |
| Venetoclax+ azacytidine | II | RFS, OS, GVHD | Recruiting | NCT04128501 | |
| Venetoclax+ azacytidine (VIALE-T) | III | RFS, OS, GVHD, MRD | Recruiting | NCT04161885 | |
| HDAC | |||||
| Panobinostat | III | OS, DFS, EFS, NRM, GVHD | Recruiting | NCT04326764 | |
| IDH2 | |||||
| Enasidenib | I | Safety, tolerability, GVHD, RFS | Recruiting | NCT03728335 | |
| Enasidenib | I | MTD, DLT, GVHD | Recruiting | NCT03515512 | |
| Enasidenib | II | OS, RFS, Safety and tolerability | Recruiting | NCT04522895 | |
| IL-15 | |||||
| N-803 | II | Relapse rate, GVHD, MRD, OS | Recruiting | NCT02989844 |
Abbreviations: PFS, progression-free survival; OS, overall survival; RFS, relapse-free survival; EFS, event-free survival; GVHD, graft-versus-host disease; MTD, maximum tolerated dose; DLT, dose-limiting toxicity; DLI, donor lymphocyte infusion; MRD, minimal residual disease; NRM, non-relapse mortality; Hh, hedgehog pathway; DNMT, DNA methyltransferase; HDAC, histone deacetylase.